Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29963651 | 1.00 | MAPT (0.65) | MAPTGAAPARP1CES2CES1 | |
| SCHEMBL8374909 | 0.87 | MAPT (0.77) | MAPTGAALMNATSHRHTT | |
| SCHEMBL1513045 | 0.82 | CES2 (0.57) | MAPTGAAPARP1CES2CES1 | |
| SCHEMBL29436991 | 0.82 | MAPT (0.69) | MAPTGAALMNANPC1TSHR | |
| SCHEMBL9403450 | 0.82 | MAPT (0.69) | MAPTGAALMNANPC1TSHR | |
| SCHEMBL2705329 | 0.82 | RECQL (0.54) | MAPTPARP1CES2CES1NPC1 | |
| SCHEMBL15628232 | 0.81 | PARP1 (0.53) | MAPTGAAPARP1CES2CES1 | |
| SCHEMBL11033976 | 0.81 | CDK5 (0.47) | MAPTGAAPARP1CES2CES1 | |
| SCHEMBL8956721 | 0.81 | PARP1 (0.49) | MAPTPARP1CES2CES1NPC1 | |
| SCHEMBL8080314 | 0.81 | MAPT (0.67) | MAPTGAAPARP1NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391664-B2 | GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor | EMORY UNIVERSITY (US) | 2025-08-19 | — | — | US | disclosed |
| US-20240294493-A1 | GluN2C/D Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptor | UNIV EMORY (US) | 2024-09-05 | — | — | US | disclosed |
| US-11981652-B2 | GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor | EMORY UNIVERSITY (US) | 2024-05-14 | — | — | US | disclosed |
| CN-114805133-A | Aryl chloroformate preparation method | 苏州星日化学有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20210017149-A1 | GluN2C/D Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptor | UNIV EMORY (US) | 2021-01-21 | — | — | US | disclosed |
| US-20210017149-A1 | GluN2C/D Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptor | UNIV EMORY (US) | 2021-01-21 | — | — | US | disclosed |
| WO-2019191424-A1 | GLUN2C/D SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTOR | EMORY UNIVERSITY (US) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019191424-A1 | GLUN2C/D SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTOR | EMORY UNIVERSITY (US) | 2019-10-03 | — | — | WO | disclosed |
| EP-0951466-B1 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2009-01-21 | — | — | EP | disclosed |
| US-7390801-B2 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| EP-0107261-B1 | (2-((NITROPYRIDINYL)AMINO)PHENYL)ARYLMETHANONES AND SALTS, THEIR USE IN MEDICINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE PREPARATION OF (2-((AMINOPYRIDINYL)AMINO)PHENYL)ARYLMETHANONES AND PYRIDO(1,4)BENZODIAZEPINES | A.H. ROBINS COMPANY, INCORPORATED (US) | 1988-09-21 | — | — | EP | disclosed |
| US-4668675-A | ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1987-05-26 | — | — | US | disclosed |
| US-4556667-A | (2-((AMINOPYRIDINYL)AMINO)PHENYL)ARYLMETHANONE INTERMEDIATES | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-12-03 | — | — | US | disclosed |
| US-4518603-A | ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INC. (US) | 1985-05-21 | — | — | US | disclosed |
| US-4503073-A | ANTIINFLAMMATORY, ANALGESIC, ANTICOAGULANT | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-03-05 | — | — | US | disclosed |
| US-4495183-A | ANTIULCER AGENTS- GASTROLINTESTINAL DISORDERS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-01-22 | — | — | US | disclosed |
| US-4480100-A | CHEMICAL INTERMEDIATES FOR ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INC. (US) | 1984-10-30 | — | — | US | disclosed |
| US-4447361-A | ANTIDEPRESSANT | A. H. ROBINS COMPANY, INC. (US) | 1984-05-08 | — | — | US | disclosed |
| EP-0107261-A2 | (2-((Nitropyridinyl)amino)phenyl)arylmethanones and salts, their use in medicine, pharmaceutical compositions containing them and their use in the preparation of (2-((aminopyridinyl)amino)phenyl)arylmethanones and pyrido(1,4)benzodiazepines | A.H. ROBINS COMPANY, INCORPORATED (US) | 1984-05-02 | — | — | EP | disclosed |
| EP-0076017-A2 | Phenyl substituted pyrido(1,4)benzodiazepines and intermediates therefor | A.H. ROBINS COMPANY, INCORPORATED (US) | 1983-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017149-A1 | GluN2C/D Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptor | GRIN2C, GRIN2A, GRIN2B | MAPT 1975/4885GAA 1607/4885PARP1 2621/4885 |
| US-20240294493-A1 | GluN2C/D Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptor | GRIN2C, GRIN2A, GRIN2B | MAPT 1505/4885GAA 1115/4885PARP1 2654/4885 |
| US-12391664-B2 | GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor | GRIN2C, GRIN2A, GRIN2B | MAPT 1505/4885GAA 1115/4885PARP1 2654/4885 |
| US-11981652-B2 | GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor | GRIN2C, GRIN2A, GRIN2B | MAPT 1505/4885GAA 1115/4885PARP1 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.